ECA Marcellus Trust I (ECTM)
OTCMKTS
· Delayed Price · Currency is USD
0.5900
0.00 (0.00%)
Jun 12, 2025, 3:54 PM EDT
ECA Marcellus Trust I Revenue
ECA Marcellus Trust I had revenue of $1.28M in the quarter ending March 31, 2025, with 103.80% growth. This brings the company's revenue in the last twelve months to $2.83M, up 20.45% year-over-year. In the year 2024, ECA Marcellus Trust I had annual revenue of $2.18M, down -24.60%.
Revenue (ttm)
2.83M
Revenue Growth
+20.45%
P/S Ratio
3.67
Revenue / Employee
1.41M
Employees
n/a
Market Cap
10.39M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.18M | -709.58K | -24.60% |
Dec 31, 2023 | 2.88M | -8.74M | -75.18% |
Dec 31, 2022 | 11.62M | 5.33M | 84.63% |
Dec 31, 2021 | 6.30M | 4.59M | 269.63% |
Dec 31, 2020 | 1.70M | -2.44M | -58.92% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EXCO Resources | 394.03M |
Cyber App Solutions | 586.70K |
Unit Corporation | 233.88M |
Pardee Resources Company | 50.63M |
Vantage Drilling International | 165.30M |
Granite Falls Energy, LLC | 409.95M |
Ferrellgas Partners | 1.94B |
CoJax Oil and Gas | 1.13M |
ECA Marcellus Trust I News
- 4 weeks ago - ECA Marcellus Trust I declares $0.052 dividend - Seeking Alpha
- 4 weeks ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 4 months ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 7 months ago - ECA Marcellus Trust I declares $0.005 dividend - Seeking Alpha
- 7 months ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 7 months ago - Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 10 months ago - ECA Marcellus Trust I Announces There Will Be No Quarterly Distribution - Business Wire
- 1 year ago - Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire